Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis
Wirksamkeit von MAPK-Inhibitoren bei Kindern mit neurodegenerativer Langerhans-Zell-Histiozytose: Ergebnisse des European Consortium for Histiocytosis
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70392 ↗Auf einen Blick
Bei 60 Kindern mit ND-LCH zeigten MAPK-Inhibitoren häufig klinische und MRT-Verbesserungen. Unerwünschte Ereignisse wurden bei 31 von 60 Patient:innen berichtet, meist nicht schwerwiegend.
Fragestellung
Wie wirksam und sicher sind MAPK-Inhibitoren bei Kindern mit neurodegenerativer Langerhans-Zell-Histiozytose?
Methode
Kohortenstudie mit Kindern mit ND-LCH, die zwischen 2013 und 2025 MAPK-Inhibitoren erhielten; klinische und radiologische Antwort mit validierten und neu entwickelten Scores.
Ergebnisse
Von 53 klinisch beurteilbaren Patient:innen zeigten 29 (55 %) eine klinische Antwort, 21 (39 %) eine Stabilisierung und 3 (6 %) eine Progression. Von 54 MRT-Follow-up-Fällen verbesserten sich 40 (74 %), 12 (22 %) waren stabil und 2 (4 %) progredient.
Schlussfolgerung der Autor:innen
Die Autor:innen berichten eine robuste Wirksamkeit von MAPK-Inhibitoren bei ND-LCH bei akzeptablem Sicherheitsprofil und sehen dies als vielversprechenden Ansatz für prospektive Validierung.
Kernaussagen
- Klinische Antwort bei 29 von 53 beurteilbaren Patient:innen
- Radiologische Verbesserung bei 40 von 54 Patient:innen
- Unerwünschte Ereignisse bei 31 von 60 Patient:innen, meist nicht schwerwiegend
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 07.06.2026. Verfasst von Francesco Pegoraro und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine University of Florence Florence Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Histiocytose France.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Neurodegenerative Langerhans cell histiocytosis (ND‐LCH) is a severe and debilitating complication of LCH with no effective treatment. In this study, we assessed the efficacy of MAPK inhibitors (MAPKi) in a large cohort of children with ND‐LCH. We included pediatric patients with ND‐LCH who received MAPKi between 2013 and 2025. Clinical and radiological responses were evaluated using validated and newly developed scoring systems. We included 60 patients and assessed the response to MAPKi in 54 (clinical n = 53, radiological n = 54). Of the 53 clinically evaluable patients, 44 (83%) presented with symptoms (impaired global functioning n = 39, 74%; neurological manifestations n = 38, 72%; and psychiatric disturbances n = 27, 51%). MAPKi were started at a median of 25 months (interquartile range [IQR] 5–67) from ND diagnosis. Clinical responses were observed in 29 patients (55%), while the remaining showed disease stabilization ( n = 21, 39%) or progression ( n = 3, 6%). Of the 54 patients with magnetic resonance imaging (MRI) follow‐up, radiological improvement was documented in 40 (74%), while 12 (22%) demonstrated stable findings, and 2 (4%) showed progression. We observed significant improvements in both clinical (P < 0.001) and MRI abnormalities (P < 0.001). None of the nine asymptomatic patients developed symptoms, while MRI lesions improved in six of them. Positive responses occurred irrespective of baseline disease severity and treatment delay. Adverse events, evaluable in 60 patients, were reported in 31 of them (52%) but were generally not severe and manageable. In conclusion, we demonstrated robust efficacy of MAPKi in ND‐LCH, with an acceptable safety profile. These findings support a promising therapeutic approach that warrants prospective validation in this challenging condition.
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine University of Florence Florence Italy.
- Department of Hematology and Oncology Meyer Children's Hospital IRCCS Florence Italy.
- French Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France.
- Radiology Department Trousseau Hospital Paris France.
- Department of Hematopoietic Stem Cell Transplantation Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology Moscow Russia.
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Oncology Kepler University Hospital Linz Austria.
ORCID-Profile: Francesco Pegoraro
Förderung
- Association Histiocytose France
Zitieren
APA
Pegoraro, F., Chalard, F., Evseev, D., Barkaoui, M., Le Louet, S., Thalhammer, J., Aladjidi, N., Salmon, A., Marec-Berard, P., Gaspari, S., De Fusco, C., Trambusti, I., Verrico, A., Raciborska, A., Svojgr, K., Křenová, Z., Slater, O., Millen, G., Ben Arush, M., …, & Donadieu, J. (2026). Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70392
Vancouver
Pegoraro F, Chalard F, Evseev D, Barkaoui M, Le Louet S, Thalhammer J, et al. Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis. HemaSphere. 2026;10(6). doi:10.1002/hem3.70392
BibTeX
@article{Pegoraro2026,
author = {Pegoraro, Francesco and Chalard, Francois and Evseev, Dmitry and Barkaoui, Mohamed and Le Louet, Solenne and Thalhammer, Julian and Aladjidi, Nathalie and Salmon, Alexandra and Marec-Berard, Perrine and Gaspari, Stefania and De Fusco, Carmela and Trambusti, Irene and Verrico, Antonio and Raciborska, Anna and Svojgr, Karel and Křenová, Zdenka and Slater, Olga and Millen, Gerard and Ben Arush, Myriam and Ashkenazi Lustig, Dana and Von Bahr Greenwood, Tatiana and Hutter, Caroline and Astigarraga, Itziar and López-Duarte, Mónica and Valero-Arrese, Lorena and Ortega Acosta, María José and van den Bos, Cor and Naeije, Leonie and Martin-Munoz, Daniel and Perrone, Anna and Mortilla, Marzia and Felician, Olivier and Idbaih, Ahmed and Héritier, Sébastien and Nanduri, Vasanta and Minkov, Milen and Henter, Jan-Inge and Sieni, Elena and Donadieu, Jean},
title = {Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70392}
}
EUVIMED